• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Earnings Upgrade Change The Bull Case For CareDx Stock (CDNA)?

    Simply Wall St·11/08/2026 05:36:33
    Listen to the news
    • CareDx reported third quarter 2026 revenue of US$139.36 million and net income of US$19.29 million, raised full year 2026 revenue guidance to US$520 million to US$530 million, and highlighted new KOAR registry data linking AlloSure Kidney donor derived cell free DNA patterns to three year kidney allograft outcomes.
    • The KOAR findings suggest AlloSure Kidney may help flag subclinical graft injury before function declines. The higher revenue outlook and recent inducement equity grants indicate management is leaning into demand for CareDx transplant testing and related services.
    • We will look at how CareDx's raised 2026 revenue guidance reshapes the existing investment narrative built around transplant testing economics.

    Scan beyond CareDx and review other transplant and healthcare testing players that screen strongly on balance sheets and fundamentals with this hand picked list of solid balance sheet and fundamentals (25 results).

    CareDx Investment Narrative Recap

    To be a shareholder in CareDx, you need to believe its transplant testing platform can keep gaining real world traction with clinicians and payers, while the firm preserves solid economics from its CLIA labs and software. The KOAR data reinforces the clinical role of AlloSure Kidney as a surveillance tool that may detect molecular injury before kidney function visibly worsens.

    The key short term swing factor is whether test volume and average revenue per test stay healthy enough to support the recently raised 2026 revenue outlook. The biggest near term risk remains a valuation reset, because CareDx trades on a premium P/E multiple and sentiment could change even if operations remain steady.

    The fresh KOAR publication is the most relevant update here. It ties early AlloSure Kidney dd cfDNA trajectories to three year graft outcomes in more than 1,100 recipients across 56 centers, with persistent or late elevations linked to higher rates of dysfunction, rejection, donor specific antibodies and allograft loss.

    For investors watching catalysts, this kind of peer reviewed outcome data can matter for adoption, guideline inclusion and reimbursement stability, which all sit behind test demand and margins. It also complements the recent revenue growth, profitability in 2026 year to date and higher full year guidance, though it does not change the valuation and execution risks already present.

    CareDx's narrative projects US$701.4 million revenue and US$80.6 million earnings by 2029. This assumes 12.1% yearly revenue growth and an earnings decrease of US$48 million from US$128.6 million today.

    Uncover how CareDx's fair value indicates a 19% potential upside to its current price, which could narrow quickly.

    NasdaqGM:CDNA 1-Year Stock Price Chart
    NasdaqGM:CDNA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate story on CareDx focuses less on KOAR style clinical momentum and more on valuation risk. The most cautious analysts were working off roughly US$651.5 million of revenue and US$44.2 million of earnings by 2029, and saw fair value about 10% below the market. That is a much harsher view on future economics. These estimates all pre date the new registry data and raised guidance, so it is worth comparing them with fresher assumptions and seeing which narrative you find more reasonable.

    Explore 3 other CareDx fair value estimates, including one that suggests it could be worth just $81.00.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and analysis.

    Looking for more investment ideas beyond CareDx?

    CareDx may sit at the center of your watchlist today, but your overall results usually depend on the mix of companies you own. A focused screener can help you quickly surface stocks that line up with your risk tolerance, income needs, or preference for strong financial footing.

    • For investors evaluating potential mispricing, you can start with a curated group of quality businesses trading on what may look like attractive valuations through the 36 high quality undervalued stocks.
    • If income stability matters to you, you may use the 7 dividend fortresses to review companies with higher yields and resilient cash flows.
    • When capital preservation is the priority, you can filter for businesses that combine healthier balance sheets with lower risk profiles by running the 31 resilient stocks with low risk scores.